Atherosclerosis
Volume 205, Issue 1 , Pages 261-265 , July 2009

Asymmetric and symmetric dimethylarginines are of similar predictive value for cardiovascular risk in the general population

  • Stefan Kiechl

      Affiliations

    • Department of Neurology, Medical University Innsbruck, Innsbruck, Austria
    • ,
  • Terry Lee

      Affiliations

    • Analytical Unit, St. George's, University of London, London, UK
    • ,
  • Peter Santer

      Affiliations

    • Department of Laboratory Medicine, Bruneck Hospital, Bruneck, Italy
    • ,
  • Graham Thompson

      Affiliations

    • Cardiovascular Division, King's College London, London, UK
    • ,
  • Sotirios Tsimikas

      Affiliations

    • Department of Medicine, University of California San Diego, La Jolla, USA
    • ,
  • Georg Egger

      Affiliations

    • Department of Internal Medicine, Bruneck Hospital, Bruneck, Italy
    • ,
  • David W. Holt

      Affiliations

    • Analytical Unit, St. George's, University of London, London, UK
    • ,
  • Johann Willeit

      Affiliations

    • Department of Neurology, Medical University Innsbruck, Innsbruck, Austria
    • ,
  • Qingbo Xu

      Affiliations

    • Cardiovascular Division, King's College London, London, UK
    • ,
  • Manuel Mayr

      Affiliations

    • Cardiovascular Division, King's College London, London, UK
    • Corresponding Author InformationCorresponding author at: Cardiovascular Division, BHF Centre, King's College, University of London, 125 Coldharbour Lane, London SE5 9NU, UK. Tel.: +44 20 7848 5238; fax: +44 20 7848 5296.

Received 29 August 2008 ,Revised 20 October 2008 ,Accepted 30 October 2008.

References 

  1. Achan V, Broadhead M, Malaki M, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol. 2003;23:1455–1459
  2. Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol. 2004;24:1023–1030
  3. Valkonen VP, Paiva H, Salonen JT, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet. 2001;358:2127–2128
  4. Schnabel R, Blankenberg S, Lubos E, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res. 2005;97:e53–e59
  5. Furuki K, Adachi H, Matsuoka H, et al. Plasma levels of asymmetric dimethylarginine (ADMA) are related to intima-media thickness of the carotid artery: an epidemiological study. Atherosclerosis. 2007;191:206–210
  6. Wanby P, Teerlink T, Brudin L, et al. Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population. Atherosclerosis. 2006;185:271–277
  7. Meinitzer A, Seelhorst U, Wellnitz B, et al. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin Chem. 2007;53:273–283
  8. Duckelmann C, Mittermayer F, Haider DG, Altenberger J, Eichinger J, Wolzt M. Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure. Arterioscler Thromb Vasc Biol. 2007;27:2037–2042
  9. Leong T, Zylberstein D, Graham I, et al. Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow-up of the population study of women in Gothenburg. Arterioscler Thromb Vasc Biol. 2008;28:961–967
  10. Dimitrow PP, Undas A, Bober M, Tracz W, Dubiel JS. Plasma biomarkers of endothelial dysfunction in patients with hypertrophic cardiomyopathy. Pharmacol Rep. 2007;59:715–720
  11. Zeller M, Korandji C, Guilland JC, et al. Impact of asymmetric dimethylarginine on mortality after acute myocardial infarction. Arterioscler Thromb Vasc Biol. 2008;28:954–960
  12. Wang J, Sim AS, Wang XL, et al. Relations between markers of renal function, coronary risk factors and the occurrence and severity of coronary artery disease. Atherosclerosis. 2008;197:853–859
  13. Mittermayer F, Krzyzanowska K, Exner M, et al. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol. 2006;26:2536–2540
  14. Maas R, Schulze F, Baumert J, et al. Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Region Augsburg study and experimental data. Clin Chem. 2007;53:693–701
  15. Kiechl S, Willeit J. The natural course of atherosclerosis. Part I. Incidence and progression. Arterioscler Thromb Vasc Biol. 1999;19:1484–1490
  16. Kiechl S, Willeit J. The natural course of atherosclerosis. Part II. Vascular remodeling. Bruneck Study Group. Arterioscler Thromb Vasc Biol. 1999;19:1491–1498
  17. Kiechl S, Lorenz E, Reindl M, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med. 2002;347:185–192
  18. Kiechl S, Willeit J, Mayr M, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol. 2007;27:1788–1795
  19. Kiechl S, Schett G, Schwaiger J, et al. Soluble receptor activator of nuclear factor-kappa B ligand and risk for cardiovascular disease. Circulation. 2007;116:385–391
  20. Xiao Q, Kiechl S, Patel S, et al. Endothelial progenitor cells, cardiovascular risk factors, cytokine levels and atherosclerosis—results from a large population-based study. PLoS ONE. 2007;2:e975
  21. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 1999;99:1141–1146
  22. Leiper J, Nandi M, Torondel B, et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med. 2007;13:198–203
  23. Chan CT, Harvey PJ, Boger R, Pierratos A, Floras JS. Dissociation between the short-term effects of nocturnal hemodialysis on endothelium dependent vasodilation and plasma ADMA. Arterioscler Thromb Vasc Biol. 2005;25:2685–2686
  24. Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function—a meta-analysis. Nephrol Dial Transplant. 2006;21:2446–2451
  25. Closs EI, Basha FZ, Habermeier A, Forstermann U. Interference of l-arginine analogues with l-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide. 1997;1:65–73
  26. Bogle RG, MacAllister RJ, Whitley GS, Vallance P. Induction of NG-monomethyl-l-arginine uptake: a mechanism for differential inhibition of NO synthases?. Am J Physiol. 1995;269:C750–C756

PII: S0021-9150(08)00775-2

doi: 10.1016/j.atherosclerosis.2008.10.040

Atherosclerosis
Volume 205, Issue 1 , Pages 261-265 , July 2009

Article Tools

* Image Usage & Resolution